NPPA caps trade margins on 137 anti-cancer medicines to save patients ₹2,500 crore
Why in news: The National Pharmaceutical Pricing Authority (NPPA) capped trade margins on 137 non-scheduled anti-cancer medicines at 30% of the retail price to reduce patient costs.
The NPPA implemented the cap on 137 non-scheduled anti-cancer medicines starting November 9. The Centre estimates the move will save patients ₹2,500 crore annually.
Prelims pointers (3)
- BodyNPPA: National Pharmaceutical Pricing Authority is the body responsible for capping trade margins on medicines.
- FactThe trade margin cap for the 137 anti-cancer medicines is set at 30% of the retail price.
- FactThe estimated annual savings for patients from this measure is ₹2,500 crore.
Mains angle
Q. Examine the effectiveness of price capping mechanisms in making life-saving drugs affordable while ensuring the sustainability of the pharmaceutical manufacturing sector.
- Market distortion: Potential impact on R&D investment and manufacturing viability for non-scheduled drugs
- Access gap: Persistence of high treatment costs beyond medicine prices as a barrier to healthcare equity
Keywords: Price Capping · Affordability · Pharmaceutical Regulation · Healthcare Equity · Market Intervention